Structural and metabolic brain changes in the striatum associated with methamphetamine abuse

Addiction

Volumn 102, Issue SUPPL. 1, 2007, Pages 16-32

  Chang, Linda ^a   Alicata, Daniel ^a   Ernst, Thomas ^a   Volkow, Nora ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Basal ganglia; Dopamine; Methamphetamine; MRI; PET

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; CREATININE; DEXTROMETHORPHAN; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; GLUCOSE; INDOMETACIN; METHAMPHETAMINE; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

AGE DISTRIBUTION; BASAL GANGLION; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; BRAIN STEM; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; FRONTAL CORTEX; GLUCOSE BRAIN LEVEL; GRAY MATTER; HUMAN; LEARNING; METHAMPHETAMINE DEPENDENCE; MICROGLIA; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SEX RATIO; VERBAL MEMORY; WHITE MATTER;

ADOLESCENT; ADULT; AMPHETAMINE-RELATED DISORDERS; BASAL GANGLIA; BRAIN; BRAIN DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; FEMALE; GLUCOSE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHAMPHETAMINE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 33847306407     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2006.01782.x     Document Type: Review

References (64)

1. Seiden L. S., Ricaurte G. Neurotoxicity of methamphetamine and related drugs. In: Meltzer H. Y. editor. Psychopharmacology: The Third Generation of Progress. New York: Raven Press; 1987, p. 359-65.
2. Melega W., Raleigh M., Stout D., Lacan G., Huang S., Phelps M. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine- induced neurotoxicity in the vervet monkey. Brain Research 1997; 766: 113-20.
3. Harvey D., Lacan G., Tanious S., Melega W. Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Research 2000; 871: 259-70.
4. McCann U. D., Wong D. F., Yokoi F., Villemagne V., Dannals R. F., Ricaurte G. A. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography. Journal of Neuroscience 1998; 18: 8417-22.
5. Volkow N., Chang L., Wang G., Fowler J., Leonido-Yee M., Franceschi D. et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. American Journal of Psychiatry 2001; 158: 377-82.
6. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M. et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 2006; 63: 90-100.
7. Volkow N., Chang L., Wang G., Fowler J., Franceschi D., Sedler M. et al. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. American Journal of Psychiatry 2001; 158: 383-9.
8. London E., Simon S., Berman S., Mandelkern M., Lichtman A., Bramen J. et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Archives of General Psychiatry 2004; 61: 73-84.
9. Ernst T., Chang L., Leonido-Yee M., Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 2000; 54: 1344-9.
10. Nordahl T. E., Salo R., Natsuaki Y., Galloway G. P., Waters C., Moore C. D. et al. Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 2005; 62: 444-52.
11. Thompson P., Hayashi K., Simon S., Geaga J., Hong M., Sui Y. et al. Structural abnormalities in the brains of human subjects who use methamphetamine. Journal of Neuroscience 2004; 24: 6028-36.
12. Chang L., Cloak C., Patterson K., Grob C., Miller E. N., Ernst T. Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biological Psychiatry 2005; 57: 967-74.
13. Jernigan T., Gamst A., Archibald S., Fennema-Notestine C., Mindt M., Marcotte T. et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. American Journal of Psychiatry 2005; 162: 1461-72.
14. Chang L., Ernst T., Speck O., Patel H., DeSilva M., Leonido-Yee M. et al. Perfusion MRI Abnormalities and Computerized Cognitive Deficits in Abstinent Methamphetamine Users. Psychiatry Research: Neuroimaging 2002; 114: 65-79.
15. Volkow N., Chang L., Wang G.-J., Fowler J., Franceschi D., Sedler M. et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. Journal of Neuroscience 2001; 21: 9414-8.
16. Wang G., Volkow N., Chang L., Miller E., Sedler M., Hitzemann R. et al. Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. American Journal of Psychiatry 2004; 161: 242-8.
17. Oh J. S., Lyoo I. K., Sung Y. H., Hwang J., Kim J., Chung A. et al. Shape changes of the corpus callosum in abstinent methamphetamine users. Neurosci Lett 2005; 384: 76-81.
18. Conant K., St Hillaire C., Anderson C., Galey D., Wang J., Nath A. Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. Journal of Neurovirology 2004; 10: 21-8.
19. Seiden L., Sabol K. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: possible mechanisms of cell destruction. NIDA Research Monograph 1996; 163: 251-76.
20. Hebert M. A., O'Callaghan J. P. Protein phosphorylation cascades associated with methamphetamine-induced glial activation. Ann N Y Acad Sci 2000; 914: 238-62.
21. Thomas D. M., Walker P. D., Benjamins J. A., Geddes T. J., Kuhn D. M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. Journal Pharmacology Experimental Therapuetics 2004; 311: 1-7.
22. Asanuma M., Miyazaki I., Higashi Y., Tsuji T., Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Annals of the New York Academy of Sciences 2004; 1025: 69-75.
23. Yamamoto B. K., Bankson M. G. Amphetamine neurotoxicity: cause and consequence of oxidative stress. Critical Reviews in Neurobiology 2005; 17: 87-118.
24. Asanuma M., Tsuji T., Miyazaki I., Miyoshi K., Ogawa N. Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal antiinflammatory drug. Neuroscience Letters 2003; 352: 13-16.
25. Thomas D. M., Kuhn D. M. MK-801 and dextromethorphan block microglial activation and protect against methamphetamine-induced neurotoxicity. Brain Res 2005; 1050: 190-8.
26. Fukami G., Hashimoto K., Koike K., Okamura N., Shimizu E., Iyo M. Effect of antioxidant N-acetyl-L-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 2004; 1016: 90-5.
27. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Shimizu E. et al. Protective effects of N-acetyl-L-cysteine on the reduction of dopamine transporters in the striatum of monkeys treated with methamphetamine. Neuropsychopharmacology 2004; 29: 2018-23.
28. Kim D. J., Roh S., Kim Y., Yoon S. J., Lee H. K., Han C. S. et al. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users. Neurosci Lett 2005; 388: 112-5.
29. Lee K. W., Kim Y., Kim A. M., Helmin K., Nairn A. C., Greengard P. Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc Natl Acad Sci U S A 2006; 103: 3399-404.
30. Corson P. W., Nopoulos P., Miller D. D., Arndt S., Andreasen N. C. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999; 156: 1200-4.
31. Lieberman J. A., Stroup T. S., McEvoy J. P., Swartz M. S., Rosenheck R. A., Perkins D. O. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
32. Chakos M., Lieberman J., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995; 345: 456-7.
33. Jacobsen L., Giedd J., Gottschalk C., Kosten T., Krystal J. Quantitative morphology of the caudate and putamen in patients with cocaine dependence. The American journal of psychiatry 2001; 158: 486-9.
34. Sowell E., Trauner D., Gamst A., Jernigan T. Development of cortical and subcortical brain structures in childhood and adolescence: a structural MRI study. Dev Med Child Neurol 2002; 44: 4-16.
35. Chang L., Smith L. M., LoPresti C., Yonekura M. L., Kuo J., Walot I. et al. Smaller subcortical volumes and cognitive deficits in children with prenatal methamphetamine exposure. Psychiatry Research 2004; 132: 95-106.
36. Jorgenson L. A., Sun M., O'Connor M., Georgieff M. K. Fetal iron deficiency disrupts the maturation of synaptic function and efficacy in area CA1 of the developing rat hippocampus. Hippocampus 2005; 15: 1094-102.
37. Van den Hove D. L., Steinbusch H. W., Scheepens A., Van De Berg W. D., Kooiman L. A., Boosten B. J. et al. Prenatal stress and neonatal rat brain development. Neuroscience 2006; 137: 145-55.
38. Brand A., Richter-Landsberg C., Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Developmental Neurosciences 1993; 15: 289-98.
39. Chang L., Ernst T., Speck O., Grob C. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. American Journal of Psychiatry 2005; 162: 361-9.
40. Nordahl T., Salo R., Possin K., Gibson D., Flynn N., Leamon M. et al. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Psychiatry Research 2002; 116: 43-52.
41. Sekine Y., Minabe Y., Kawai M., Suzuki K., Iyo M., Isoda H. et al. Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology 2002; 27: 453-61.
42. Smith L. M., Chang L., Yonekura M. L., Grob C., Osborn D., Ernst T. Brain proton magnetic resonance spectroscopy in children exposed to methamphetamine in utero. Neurology 2001; 57: 255-60.
43. Simon S., Domier C., Carnell J., Brethen P., Rawson R., Ling W. Cognitive Impairment in individuals currently using methamphetamine. American Journal of Addiction 2000; 9: 222-31.
44. Kalechstein A. D., Newton T. F., Green M. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. Journal of Neuropsychiatry and Clinical Neuroscience 2003; 15: 215-20.
45. Salo R., Nordahl T., Possin K., Leamon M., Gibson D., Galloway G. et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Research 2002; 111: 65-74.
46. Salo R., Nordahl T. E., Moore C., Waters C., Natsuaki Y., Galloway G. P. et al. A dissociation in attentional control: evidence from methamphetamine dependence. Biol Psychiatry 2005; 57: 310-3.
47. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H. et al. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. American Journal of Psychiatry 2001; 158: 1206-14.
48. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K. et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. American Journal of Psychiatry 2003; 160: 1699-701.
49. Moszczynska A., Fitzmaurice P., Ang L., Kalasinsky K. S., Schmunk G. A., Peretti F. J. et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004; 127: 363-70.
50. Johanson C. E., Frey K. A., Lundahl L. H., Keenan P., Lockhart N., Roll J. et al. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 2006; 186: 620.
51. Commins D. L., Seiden L. S. alpha-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex. Brain Res 1986; 365: 15-20.
52. Volkow N., Chang L., Wang G., Fowler J., Ding Y., Sedler M. et al. Low level of brain dopamine d(2) receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. American Journal of Psychiatry 2001; 158: 2015-21.
53. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R. et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 1997; 386: 830-3.
54. Wang G. J., Volkow N. D., Fowler J. S., Logan J., Abumrad N. N., Hitzemann R. J. et al. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropsychopharmacology 1997; 16: 174-82.
55. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Hitzemann R., Ding Y. S. et al. Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol Clin Exp Res 1996; 20: 1594-8.
56. London E. D., Berman S. M., Voytek B., Simon S. L., Mandelkern M. A., Monterosso J. et al. Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. Biol Psychiatry 2005; 58: 770-8.
57. Voytek B., Berman S. M., Hassid B. D., Simon S. L., Mandelkern M. A., Brody A. L. et al. Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse 2005; 57: 113-5.
58. Molitor F., Ruiz J., Flynn N., Mikanda J., Sun R., Anderson R. Methamphetamine use and sexual and injection risk behaviors among out-of-treatment injection drug users. American Journal of Drug and Alcohol Abuse 1999; 25: 475-93.
59. Halkitis P., Parsons J., Stirratt M. A double epidemic: crystal methamphetamine drug use in relation to HIV transmission among gay men. Journal of Homosexuality 2001; 41: 17-35.
60. Wang G., Chang L., Volkow N., Telang F., Logan J., Ernst T. et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004; 127: 2452-8.
61. Porrino L. J., Lyons D., Smith H. R., Daunais J. B., Nader M. A. Cocaine self-administration produces a progressive involvement of limbic, association, and sensorimotor striatal domains. Journal of Neuroscience 2004; 24: 3554-62.
62. Ito R., Dalley J. W., Robbins T. W., Everitt B. J. Dopamine release in the dorsal striatum during cocaine-seeking behavior under the control of a drug-associated cue. Journal of Neuroscience 2002; 22: 6247-53.
63. Volkow N. D., Wang G. J., Telang F., Fowler J. S., Logan J., Childress A. R. et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. Journal of Neuroscience 2006; 26: 6583-8.
64. White N. M., McDonald R. J. Multiple parallel memory systems in the brain of the rat. Neurobiology of Learning and Memory 2002; 77: 125-84.